I am an independent trader of equities and options on equities as well as some commodities. I trade over timeframes that make "technical analysis" useless - namely ALL time frames. My trading goal is usually a 5% ROI within a "short" time. Previously to full time markets participation I was a Research Chemist working in the Specialty Chemical Industry. I was/am particularly skilled in Molecular Modeling, Rheology, Data Acquisition and Analysis. I have deep experience in Artificial Neural Networks and Genetic Algorithms. My current focus is in studying and applying non-Normal (Gaussian) price return distributions for modeling Option Premia. I use home-brew code for advanced Time Series Analysis. Trading the "Market" is the hardest way to make "easy" money. In general, I am a Wild And Crazy Guy.
Dustin Moore is a researcher and analyst focusing on overlooked and undervalued investments. He enjoys analyzing under-the-radar companies with massive upside potential and those with favorable risk/reward ratios.
On Twitter! @dustinrmoore https://twitter.com/dustinrmoore
I worked in New York's financial sector for almost exactly 20 years, mostly as a healthcare analyst (drugs, biotech, and medical devices), but also as an assistant research director, portfolio manager, and options strategist. My last formal job had me in charge of Value Line's premium priced "Select" and "Special Situation" products. The former highlights the company's top stock pick of each month and the latter introduces relatively small companies. I quit that job in June, 2009 for reasons that a dozen or so confidentiality agreements preclude my discussing. In September of that year, I launched 3DimensionalResearch.com (3DR), which allows me to continue doing what I was doing previously.
I am a strong believer in maximum transparency, in both personal and business relationships. So, in that vein:
A google search will show that my former employer sued 3DR and me in November, 2009 for copyright infringement, hot news misappropriations, and the proverbial kitchen sink. Although a search won't show this, unfortunately, I represented myself in a federal courtroom in December and, in accordance with the judge's instructions, the case was settled in a matter of minutes.
Additional Disclosure: 3DR has been a financial failure thus far, in terms of getting subscribers. I detest marketing and few people want to pay for information anymore, least of all from a no-name website. That said, the vast majority of my recommendations have done very well and my personal portfolio is doing extraordinarily well (65.5% in 2013) since I tend to follow most of my own recommendations, the "event driven special situations," in particular.
Gold Traders offers market analysis based on macroeconomics and geopolitical events, designed to alert investors to new market trends before they develop. We successfully alerted investors to sell at the metals market top in 2013 -- and we continue to find new ways for precious metals investors to profit in both bullish and bearish market environments.
Visit Gold-Traders.com for the latest investment alerts and trading tutorials.
After completing both a PhD in physiology and an MBA, I am interested in leveraging both areas of expertise to provide in depth analysis of the biotech sector. I began analyzing and covering biotech stocks in 2006. My interest in this sector is a result of my past experience in this industry which ranges from R&D to strategic management at several large and small biotech firms. With a broad scientific background and formal training in finance, I seek to leverage my knowledge and industry experience to provide a deep understanding of the markets and science that drive value in microcap healthcare stocks.
The material presented in these reports is provided for information purposes only and is not to be used or considered as a recommendation to buy, hold or sell any securities or other financial instruments. Information contained herein has been compiled and prepared from various public and industry sources that I believe to be reliable; however, no representation or warranty is expressed or implied as to the accuracy or completeness of the information. Such information is provided with the expectation that it will be read as part of a broader analysis and should not be relied upon on a stand-alone basis. Past performance should not be taken as an indication or guarantee of future performance, and I make no representation or warranty regarding future performance. The opinions expressed in this report reflect my judgment as of the date of this report and are subject to change without notice. These reports are not an offer to sell or a solicitation of an offer to buy any securities. The offer and sale of securities are regulated generally in various jurisdictions, particularly the manner in which securities may be offered and sold to residents of a particular country or jurisdiction. Securities discussed in these reports may not be eligible for sale in some jurisdictions. To the full extent provided by law neither myself nor any other person accepts any liability whatsoever for any direct or consequential loss arising from any use of this report or the information contained herein. I am not on the Board of Directors of a covered company. I do not invest in the securities of the company that is the subject of these reports unless otherwise indicated. I have not been compensated by the company that is the subject of these reports.
The Life Sciences Report features leading investment coverage of the life sciences sector, including biotechnology, pharmaceuticals, tools & diagnostics, and medical devices. A Streetwise Reports publication. www.TheLifeSciencesReport.com
The Pendulum blog is an ongoing discussion of portfolio positions, investment ideas and market trends. As an investor I try to use my independence, flexibility and speed to my advantage.
I write three types of articles: (i) stock-specific articles, (ii) analysis of earnings estimates and (iii) overviews of the market that examine different asset classes. I hope you find them interesting and feel free to comment on the articles; I like the feedback. Thanks for reading!
I started thinking about stock prices in terms of a pendulum after reading Howard Marks' investor letters. Marks is the most perceptive investor about the role of investor psychology in the stock market and industry cycles. I always try to incorporate "pendulum thinking" in my analysis, meaning that it is important to think about the intrinsic value of a company as well as how investor psychology is going to drive the stock price to overshoot and undershoot that value.
I am a generalist. I am not an expert in any one sector or asset class. I have found that there is value in listening to generalists as well as experts, but it is important to be able to distinguish between the two. As a generalist, I try to add value by thinking about the relationships between things and comparing various parts of the market. Generalists can be helpful in avoiding tunnel vision and, hopefully, adding some common sense.
I like to establish a long term outlook for a company and then invest using shorter timeframes. I may be bullish on a stock and still sell it if I think it went up too much or if have concerns about the overall market. I don't mind moving to the sidelines and getting back in at a later point and I sometimes prefer to sell before earnings to reduce risk. I may invest in the opposite direction of my long term view if I think the market over-reacted one way or another. I like to hold positions for the long term, but I use stops to cut my losses. There is a difference between a good company and a good stock. Everybody has a different investing style, experience, tax status, risk tolerance, comfort range, etc., so please note that nothing that I write should be used as investment advice.
Disclaimer: The opinions expressed here should not be construed as investment advice. This is not tailored to specific investment objectives. Reliance on this information for the purpose of buying the securities to which this information relates may expose a person to significant risk. The information contained in this article is not intended to make any offer, inducement, invitation or commitment to purchase, subscribe to, provide or sell any securities, service or product or to provide any recommendations on which one should rely for financial, securities, investment or other advice or to take any decision. Readers are encouraged to seek individual advice from their personal, financial, legal and other advisers before making any investment or financial decisions or purchasing any financial, securities or investment related service or product.
Information provided, whether charts or any other statements regarding market, real estate or other financial information, is obtained from sources which we and our suppliers believe reliable, but we do not warrant or guarantee the timeliness or accuracy of this information. Nothing in this article should be interpreted to state or imply that past results are an indication of future performance.
THERE ARE NO WARRANTIES EXPRESSED OR IMPLIED AS TO ACCURACY, TIMELINESS, COMPLETENESS, OR RESULTS OBTAINED FROM ANY INFORMATION IN THIS ARTICLE OR ANY LINKED WEBSITE.
I just recently caught the investing bug and started taking an active interest in my (presently meager) portfolio in October, 2011. Turns out I'm not too bad at making my own picks, and I really enjoy doing my own research. So far my picks have significantly outperformed those of my high-priced broker (by about 10X). I've only got about 17 years left before I'll have to retire, and I've gotta get a move on if I want to enjoy my Golden Years and not end up having to work as a WalMart greeter on the graveyard shift. Seeking Alpha and The Motley Fool have helped me learn a great deal in a short period of time, but I've got a long way to go. I'm currently focused on building a portfolio of solid, stable dividend growth ... More stocks, with some pure growth (speculative) positions thrown in. At present I have 30 positions that yield an average of 5.3% in dividends. I'm hoping to learn more about options and save enough on the side so I can start playing with trading options; I'm looking forward to actively managing my portfolio in my retirement, and want to get really good at it before then.
Ernie Zerenner, co-founder of PowerOptions, has been an active stock trader for over 40 years and an avid options trader for more than 20 years. Each Saturday he would look in the newspaper to find options with the best return Covered Calls. This process would literally take hours. First he had to find the stocks that looked promising. Second, he had to find the best options. Finally, he had to do calculations to determine the best returns. Ernie thought, "There has to be a better way." In 1997, a colleague and Ernie had an idea - Why not use the power of the Internet to gather the data and use computers to do the calculations. We built a web site to do just that. Ernie used the site to find the best options instead of using the newspaper. Ernie was so excited that he showed it to fellow traders and let them use it also. It was so successful that he decided to open the web site up to the public...and PowerOptions was born. Since 1997, PowerOptions has built a winning team to support and continue development of the tools and strategies offered. PowerOptions now includes over 150 pages in its award winning web site and cover 23 of the most popular option strategies. PowerOptions has been reviewed and acclaimed by many in the industry: Forbes, AAII, Active Trader Magazine, New York Post, and Nightly Business Report to name a few. PowerOptions is so innovative, the US Patent and Trade Office issued us patents in 1997 and 2007. By 2000, we took over operation of OptionFind.com, a site that has similar options search engine capabilities. Many of our subscribers told us that they loved the system, but had trouble finding the time to do their own options research. They suggested that we offer an advisory newsletter service. We released such a service under the name PowerOptionsApplied.com in 2005. This service uses our expertise and patented tools to search out, publish, and manage what we feel are great option trades. We offer Covered Calls, Diagonal Spreads and Iron Condors so far, more of your favorite strategies to come. Also in 2005, we released our first publication in the options education arena. Covered Calls: Aggressive Strategy for the Conservative Investor is a self-study course. It includes a DVD, 130 page book, and a workbook to help beginning option traders learn the basics of the most popular option trading strategy: Covered Calls. The course also includes 2 free months of the PowerOptions online subscription service. In 2008, we released our second and third publications to compliment our self-study covered calls kit... Naked Puts: Power Strategies for Consistent Profits is a beginner level text that illustrates the details of using cash secured puts to acquire stock at a discount and generate income. It covers the basics of the strategy from understanding the theory, entering a new trade and covers all the way through trade management. Protective Option Strategies: Married Puts and Collars covers reliable strategies to generate consistent income and provide insurance, especially during times of financial crisis and uncertainty. Topics of discussion include tips on entering protective strategies and the theories behind them, as well as selecting the right stocks and proper protective combinations for investing in today's volatile market. Also in 2008, we purchased the rights to the RadioActive Trading methodology. This investing methodology is just one strategy that options investors can use, but trading "RadioActively" gives investors a great chance of making money and keeping their capital while they do it. The RadioActiveTrading.com site offers plenty of educational materials to get any investor with any experience level into options trading with the ammunition he needs to be successful. After learning the methodology, investors can implement the trading style themselves with the help of the PowerOptions tools, or look over the shoulder of the RadioActive trading staff as they pick and publish trades to the FISSION advisory newsletter subscribers. Most recently, in 2010, we published our fourth educational text. Iron Condor: Neutral Strategy for Uncommon Profit. The concepts, ideas, rules-of-thumb and real-world examples presented in the text have been gleaned from the PowerOptionsApplied newsletter's successful trading of the strategy. Readers can take the lessons learned by the PowerOptionsApplied newsletter and repeat the good and forgo the bad in order to profitably invest using the Iron Condor strategy. This text presents real-world examples, real-world profits and real-world mistakes, the concept of optimally trading Iron Condors by balancing risk, reward, volatility, stop-losses and other parameters to achieve the best results from trading the strategy. Ernie and his staff are active investors; they use the PowerOptions tools and research every day. The company's staff is personally committed to providing you with quality service and an exceptional value. Please feel free to contact us with any suggestions or problems that you may have. If you are inside the continental US, our toll-free phone number is: (877) 992-7971, for users outside the country, 302-992-7971. If it is easier for you, you can also send us an email message by clicking any of the email links at the bottom of every page in our site.
Gary Dorsch (http://seekingalpha.com/by/author/gary-dorsch/) originally worked for Charles Schwab, and his analysis of the markets have been read for years by hedge fund managers and other professional investors. He now writes Global Money Trends (http://sirchartsalot.com/newsletters.php), a respected investment newsletter covering global asset markets. We think Gary is exceptional: he's one of the few writers who covers global markets with insight and brevity, and shows US-based investors how to invest in them. You'll find his work on ETF Investor and the international blogs.
Timothy Lutts heads one of America’s most respected independent investment advisory services, publishing 11 advisories to over 250,000 subscribers around the world. He leads a dedicated team of professionals who serve investors with high-quality investment advice based on time-tested Cabot systems. Tim is also the chief analyst of Cabot Stock of the Month.
A growth stock and market timing expert, Michael Cintolo is chief analyst of Cabot Market Letter and Cabot Top Ten Trader. Since joining Cabot in 1999, Mike has uncovered exceptional growth stocks and helped to create new tools and rules for buying and selling stocks.
A researcher and writer for over 30 years, Paul Goodwin has been a member of the Cabot investment team and chief analyst of Cabot China & Emerging Markets Report since 2005. Paul is also the editor of the Cabot Wealth Advisory, a free email newsletter that offers independent, no-nonsense investment advice on how to build long-lasting wealth from Cabot’s team of analysts and editors.
J. Royden Ward applies his 40 years of investment research and portfolio management experience to his role as chief analyst of Cabot Benjamin Graham Value Letter. He developed a computerized model of stock selection based on formulas created by investment legend—and Warren Buffett mentor—Benjamin Graham.
Jacob Mintz is a professional options trader and chief analyst of Cabot Options Trader. Using his proprietary options scans, Jacob creates and manages positions in equities based on risk/reward and volatility expectations. Jacob developed his proprietary risk management system during his years as an options market maker at a top-tier options trading company in Chicago.
Chloe Lutts Jensen is the chief analyst of Cabot Dividend Investor, and the third generation of the Lutts family to join the family business. She developed Cabot's proprietary Individualized Retirement Income System (IRIS) and Cabot Dividend Investor to deliver income-oriented advice that could provide both high income and peace of mind to investors thinking about retirement.
Proactiveinvestors is a leading multimedia news organization, investor portal and events management business with offices in New York, Sydney, Toronto and London.
Proactiveinvestors operates five financial websites in four languages providing breaking news, comment and analysis on hundreds of listed companies across the globe daily. We are one of the fastest growing financial media portals in the world.
The group also operates hugely successful “investor forums” where three or four companies present to an audience of high net sophisticated investors, fund managers, hedge funds, private client brokers and analysts.
Ian Mclelland founded Proactiveinvestors in 2006 as a way to channel his own views on companies small and mid-cap public companies. What started as a hobby quickly turned into a full time job as the website's readership exploded.
Michael Murphy grew up in Newark, Delaware, which a sign at the city limits proclaimed: “The Educatoinal Center of the State.” After graduating from the public schools he earned an A.B. cum laude from Harvard College and began working as a COBOL mainframe programmer on an IBM 1401 in the mid-1960s. Lured to California by the Summer of Love and better music than American Bandstand in nearby Philadelphia, he became a systems analyst and programmer for American Express, assigned to help integrate their newly-acquired San Francisco investment operations with the parent company's systems in New York. As that project ended early in 1970, a fortuitous opportunity to make a career change to Security Analyst opened up, and he leaped at the chance. His first recommendation was to sell Memorex at $172 at the very bottom of the 1969-1970 bear market. During the subsequent two-year market rally, Memorex went to $2 a share, thus convincing him that it is indeed a market of stocks rather than a stock market.
He earned his Chartered Financial Analyst (CFA) designation in 1975, the same year The Capital Group/American Funds acquired the American Express mutual fund group. He commuted to Capital in Los Angeles for over five years, getting on a first-name basis with many flight attendants. After the introduction of the IBM PC in April 1981, he left Capital to found the California Technology Stock Letter. In 1997 he also became the founding editor of Technology Investing, which acquired CTSL in 2003 and changed its name to New World Investor in 2007.
In the 1970s he invented and patented a stock value calculator, and in the 1980s he served as the CEO of two software companies. In 1997 he authored the business best-seller Every Investor's Guide to High-Tech Stocks and Mutual Funds, and he has a forthcoming book on investing in a hyperinflation. In addition to investing, his interests include a biodynamic, organic permaculture farm to raise rare-breed animals, heritage seed crops and children. For many years he held the Class I/E record for electric cars at the Bonneville Salt Flats, and in 2001 he narrowly missed the world record for electric hydroplanes. He expects to go back to Bonneville in 2019 to reclaim the electric car record with his then-16 year old daughter driving. You are all invited to watch or help out.
Ed Silverman is the founding editor of Pharmalot and a prize-winning journalist who has covered the pharmaceutical industry for the past 15 years for The Star-Ledger of New Jersey, The Pink Sheet and, currently, as an editor-at-large for Med Ad News and R&D Directions.
Sheff can be followed at twitter.com/SheffStation. He is an investor & trader of big board, small cap, and biotech stocks. He uses fundamental analysis and extensive DD (due diligence) to trade. Over the years, he has learned a great deal about how the FDA works and what they look for when considering a drug for approval. His success record in stock picking and many yrs in the biotech & pharmaceutical industry has helped him in his analysis of biotech & pharma stocks. His goal is to find undervalued companies and help the individual investor by discussing clinical data that could be relevant in how the FDA will make a decision for a drug or clinical data.
Do your own due diligence and never buy a stock based on what Sheff discusses or says.
Sheff is is not a licensed broker or financial advisor of any kind nor is he qualified to act as an investment advisor. His articles are written for discussion purposes only. None of the information written about by Sheff is to be construed as financial or investment advice. The information shared is not to be construed as an offer to buy or sell any security. Sheff works diligently to avoid misstatements of fact, but advises all investors to consult a licensed profession prior to making an investment in any stock he discusses. The information on this site is gathered from sources available to the public
Sheff's hobbies are reading, family, and helping people. I enjoy the work I do as a Chemo Specialist in many cancer centers and the volunteer work as a member with a Cancer Organization where I raise money for awareness & other programs vital for children with different forms of cancer.
Justin M. Hall is an extremely accomplished independent financial analyst with more than a decade of experience in the financial markets. He consistently provides expertise to a variety of financial clients and is known for his successful market predictions. Between 2010 and 2014 Justin made 239 specific market recommendations via his online subscription service with an 80% accuracy rate. He has produced enduring results for a variety of clients including those who trade stocks, invest their own money, desire personal wealth management, and institutional investors. But more than an analyst, Justin is a person who influences and persuades, whose judgement is well respected and highly trusted, and whose opinion is sought by those searching for financial and investment advice.
Justin received his undergraduate degree from Indiana State University and attended law school at Indiana University. His desire to serve the financial and investment needs of individual clients led him to start Rx Investors.com, an online subscription service that connected individual investors with his expert analysis. Subscribers from all over the world utilized Justin’s advice to generate market income and grow their individual portfolios. Many of these subscribers and clients continued to seek Justin’s analysis and advice for many years, appreciating his unique perspective on the financial industry.
A variety of financial outlets have recognized Justin’s expertise and highlighted his work including the Orange County Business Journal, Seeking Alpha, and Zack’s Investment Research. These industry connections have allowed Justin to lend his expert advice to others and expand his influence.
Reggie Middleton is the personification of the freethinking maverick — the ultimate nonconformist as it applies to macro strategies, investment, and analysis. He uses his background and knowledge in new media, distributed computing, risk management, insurance, financial engineering, real estate, corporate valuation, and financial analysis to pursue, analyze, and capitalize on global macroeconomic opportunities.
Finding most available research lacking, both in quality and quantity, Mr. Middleton assembled his own talented research staff. As forensic research is a lynchpin for his own investing, "to actually put food on the table," he stands behind it as doing what it is supposed to do - illustrate, elucidate and educate. He does not sell advice or research. He is an entrepreneur who exists outside of mainstream corporate America and Wall Street. This allows him the freedom to do things that many cannot—perform without conflicts of interest and corporate politics.
Mr. Middleton prides himself on developing some of the highest quality, actionable research available - regardless of price. He welcomes any and all to peruse his blog of freely available analysis, opinion and participatory social media; use his custom tools, download files, interact with the community and make critical comparisons from a results orientated perspective.
Reggie believes ideas and implementations are improved and fine-tuned when bounced off of the collective intellect of the many, in lieu of that of the few - in essence, a form of collaborative open source financial analysis.
Visit his blog Boom Bust Blog. (http://boombustblog.com/)
Nutritionist/MD/Biotech investor. I have little time to discuss the general market, anything I cannot change or other irrelevant topics that dominate seekingalpha and are the products of its top 100 members. I put my money where my mouth is and adhere to sound DD. Capitalism favors the bold and I intend to honor that. For any naysayers I'll leave the 15% yearly gains to you and you can leave the world to me. Embers will be the only thing left in my path.
The Rational Walk was created to provide a platform to publish equity research based on value investing principles. We believe that diligent and thorough security analysis has the potential to identify opportunities in the financial markets for the small number of investors who truly have long time horizons and the appropriate temperament to ignore short term market fluctuations. The Rational Walk’s extensive coverage of Berkshire Hathaway has been mentioned in several news articles.
John received his PhD in chemistry in the research group of Nobel Laureate Donald Cram in 1987 and his MBA from the Anderson School of Management at UCLA in 2009. His research career spans 16 years performing drug discovery research in metabolic diseases, cancer, HIV infection, antibacterials, and Alzheimer's disease. In 2011 John joined Sagient Research Systems as a Biotechnology Analyst. In 2013 he joined Zack's Small Cap Research as an Analyst.
On Twitter: @johntuckerphd
As John is neither licensed nor qualified to act as an investment advisor, his articles are written for discussion purposes only and should not be construed as investment advice. He makes a reasonable effort to avoid misstatements of fact, but advises all investors to consult primary sources prior to making an investment.
EP Vantage is a forward-looking comment and analysis service tailored to the needs of pharma and finance professionals, focusing on the events that will define the future of companies, products and therapy areas. Written by experienced journalists, EP Vantage provides timely financial analysis of regulatory and patent decisions, marketing approvals, licensing deals, and M&A, giving fresh angles and insight to both current and future industry triggers. EP Vantage is powered by EvaluatePharma, the industry leader in consensus forecasts.
Philstockworld.com is the fastest growing stock and option newsletter on the Web. "High Finance for Real People - Fun and Profits" is our motto and our Basic and Premium Chat Sessions offer readers a chance to speak to Phil live during the trading day as well as authors like Optrader, Sabrient, Income Trader and Trend Trader - who send out Alerts during the market sessions and discuss trade ideas live with Members.
We even have a new low-cost "Trend Watcher" Membership that lets readers view our chat sessions without directly participating a great solution for people who want to test-drive the site and profit from our experience! Trend Watchers get to view all of our Chat Archives, weekly Webinars - as well as the amazing PSW Wiki, which gives you Phil's recent opinions and trade ideas as well as technical and fundamental analysis of hundreds of stocks that we follow.
Philip R. Davis is a founder of Phil's Stock World (www.philstockworld.com), a stock and options trading site that teaches the art of options trading to newcomers and devises advanced strategies for expert traders. Mr. Davis is a serial entrepreneur, having founded software company Accu-Title, a real estate title insurance software solution, and is also the President of the Delphi Consulting Corp., an M&A consulting firm that helps large and small companies obtain funding and close deals. He was also the founder of Accu-Search, a property data corporation that was sold to DataTrace in 2004 and Personality Plus, a precursor to eHarmony.com. Phil was a former editor of a UMass/Amherst humor magazine and it shows in his writing -- which is filled with colorful commentary along with very specific ideas on stock option purchases (Phil rarely holds actual stocks).
Visit: Phil's Stock World (www.philstockworld.com)
I'm an experienced options/futures trader and freelance writer. I've covered the options market for various companies for the past 12 years. Prior to that, I worked as an institutional sales trader for a New York-based institutional brokerage firm. I'm now in Chicago and you can catch my Friday mornings on CBOE TV. Please visit the Options Idea Central blog for recent commentary and options trading ideas.
Mike Havrilla is a former pharmacist (retail and home infusion settings), biotech stock trader, and writer with experience that includes full-time online trading since 2009, working as a full-time pharmacist from 2004-2009, and writing for investors since 2007. Mike holds Doctor of Pharmacy (PharmD) and Bachelor of Science (Biology) degrees from the University of Pittsburgh and worked in the pharmaceutical industry for Wyeth prior to pharmacy school. He is also an avid runner and has completed over 20 marathons with a personal best time under three hours for the 26.2 mile race and under 80 minutes for the half marathon. Mike merged his former publishing business with BioRunUp.com / Mark Messier in October 2010, creating a new online biotech stock research and trading subscription service.
optionMONSTER® provides stock market insight, advanced options education, and actionable trade ideas to meet the needs of do-it-yourself investors. Our content is published daily at our website www.optionmonster.com in the form of free stories, webcasts, webinars, educational offerings and subscription services.
I'm Ruthanne Williams Roussel, a reformed sell-side analyst who has covered the obesity space for several years. Unlike anyone else I've met who covers these companies for the big banks, I am among the target market for most of these products, which allows me to bring a consumer's perspective. In a past life, before the Asian/Russian currency crisis of 1998, I was an emerging markets specialist. Since then, I've been drawn to the closest things I can find: special situations and small-cap stocks.
Dr. Stephen Leeb is a recognized authority on the stock market, macroeconomic trends and commodities, especially oil and precious metals.
Dr. Leeb is founder of the Leeb Group, which publishes a line of financial newsletters including The Complete Investor, Leeb Income Performance Letter, Leeb Income Millionaire, Brain Trust Profits, Leeb's Real World Investing and Leeb's Aggressive Trader. His total readership exceeds 100,000. The Complete Investor newsletter has earned two awards for Editorial Excellence, as has Leeb Income Performance.
Dr. Leeb is also Chairman and Chief Investment Officer of a New York-based registered investment advisory firm. Dr. Leeb has been managing large cap growth portfolios since 1999.
Dr. Leeb sits on various boards sharing his strategic perspectives on financial markets and natural resources. Since 2008, Dr. Leeb has been a Director of Plain Sight Systems, a technology holding company centered at Yale University. Plain Sight owns a world-class patent portfolio in areas such as information organization/search, computational analytics, electro-optics, and spectroscopy. These technologies are licensed to Fortune 500 companies and used as part of private buyouts and venture spin-offs.
As part of Plain Sight, Dr. Leeb also sits on the board of Water Intelligence plc, a publicly listed company in England, operating in the water management space and Deep Markets Corporation, a division of Plain Sight developing next generation risk management applications.
Dr. Leeb is also Head of the Advisory Board of Leor Exploration & Production LLC (since 2006 - present) and a member of the advisory boards of Electrum USA Ltd. (since 2007) and Los Gatos. Each of these companies explore for natural resources, especially precious metals and energy.
Dr. Leeb is the author of eight books on investments and financial trends. His latest book, Red Alert: How China's Growing Prosperity Threatens the American Way of Life (Business Plus, 2012) predicts China's coming global domination.
An earlier book, The New York Times best seller, The Coming Economic Collapse: How You Can Thrive When Oil Costs $200 a Barrel (Warner Books, 2006), predicted that tightness in global energy supplies would cause the American economy to oscillate between periods of recession and high inflation this century.
Dr. Leeb’s best seller, The Oil Factor: Protect Yourself and Profit from the Coming Energy Crisis (Warner Books, 2004), outlined the relationship between oil prices and stock market performance and accurately predicted the subsequent surge in oil prices. The book was rated among the top investment books of the year by Stock Trader's Almanac 2005.
His earlier best seller, Defying the Market: Profiting in the Turbulent Post-Technology Market Boom (McGraw-Hill; 1999) predicted the collapse of technology stocks and the growing importance of oil, and other hard assets during the 21st century. The book was selected by Library Journal as one of the Best Business Books of 1999.
His first book Getting in on the Ground Floor (Putnam, 1986) predicted the secular bull market in financial assets and the fall in inflation. The book was a main selection of the Money Book Club.
Dr. Leeb earned his Bachelor's degree in Economics from the University of Pennsylvania's Wharton School of Business. He then completed both a Master's degree in Mathematics and a Ph.D. in Psychology at the University of Illinois.
Color Splat (colorsplatgame.blogspot.com) generates random colors and shapes which you drag around to create your very own contemporary art.
Magic Word (magicwordgame.blogspot.com) generates a matrix of random letters. Find words displayed across, back, up, down and diagonally in a table. Box the words and then arrange them into fun phrases.
Scramble Word (scramblewordgame.blogspot.com) builds phrases and sentences by switching the positions of letters and shifting entire rows and columns in a table grid.
Mike Huckman is CNBC’s Pharmaceutical Reporter covering the drug, biotechnology and medical device industries. Huckman is based at the network’s global headquarters in Englewood Cliffs, N.J.
Huckman joined CNBC in September 2000 after nine years at WXYZ-TV in Detroit where he was one of the station’s lead reporters. Prior to WXYZ-TV, he served as a general assignment reporter at KGUN-TV in Tucson, Ariz., KBCI-TV in Boise, Idaho, and as an anchor/producer for the Montana Television Network.
Huckman has won numerous awards for his reporting, including three Michigan News Emmys, one for Business and Financial reporting, as well as a first place News Series Award from the Michigan Association of Broadcasters. Huckman earned a Bachelor of Arts degree in journalism from the University of Southern California.
Thomas Ryan, CEO of Doddsville Investments (http://doddsvilleinvestments.com/), received his B.S. in Finance from Tulane University in 2000, and an M.B.A. at the University of Miami in May 2008 with a concentration in finance. Mr. Ryan approaches markets with a broad view of the economy, relatively simple investment themes and his analysis is not restricted by daily or weekly trading trends that sometimes plague financial institutions. He has traded his own portfolio with the same macro viewpoint he will use for the Fund. The Fund’s investment objective is to maximize long-term total returns, in variable market and economic conditions, while emphasizing preservation of capital.
Over the past several years, the General Partner has been developing and refining a top-down macroeconomic approach to identify securities and indices that would be suitable for opportunistic investment. The General Partner focuses on general economic conditions in the United States and abroad, and based on broad themes and trends, analyzes whether certain pockets of various markets appear over or under valued, thus presenting opportunities to capitalize on imbalances. The General Partner’s strategy is directional, meaning its investments will be selected to go in a particular market direction and not be “market neutral.”
As part of its macro-level approach, the General Partner incorporates both “qualitative” and “quantitative” principles to identify market conditions, entry and exit points and trading ranges and patterns with the goal of identifying attractive investment opportunities. For instance, it will qualitatively evaluate whether unrealistic assumptions are built into certain indices or pockets of the market and then use a quantitative approach to drive and monitor particular investments selections.
Karen Arnie is the Founder of Stock Tips, LLC and MarketBeatingStocks.com (http://www.MarketBeatingStocks.com/). MarketBeatingStocks.com (http://www.MarketBeatingStocks.com/) deploys a systematic investment and portfolio management strategy using proprietary technology and screening techniques. Ms. Arnie has been a long-time investor in the stock market and an active researcher of stock selection and portfolio management strategies. She continually researches and tracks performance against various buy and sell strategies in order to optimize her approach to investing. Through MarketBeatingStocks.com (http://www.MarketBeatingStocks.com/), she shares her results on portfolio performance, investment strategy, and offers timely information on stocks and options that are bought and sold.
I specialize in small and micro-cap stocks that are largely underfollowed but offer us the greatest possible risk/reward scenario.
My passion is finding little known companies poised to explode, writing about them, and then investing in them right alongside my readers!
Part of that process involves giving you full access to my real-time thought processes and trades as soon as they take place, and following up with those actionable alerts with a full report as to why, when, where and how a trade was executed and why a certain company was singled out by me for either buying or selling.
I don't try and cover every company under the sun, in fact that's a quick way to screw yourself over and never beat the market.
Instead, I focus narrowly on a select few companies/industries, learn them inside and out, so that I can provide you with the most comprehensive and detailed information to make sure you crush the market for years to come.
Follow me on Twitter for REAL-TIME Alerts and follow me on my stock blog for more in depth reporting.
Interactive Brokers' Traders Insight is a free online blog drawing together financial market commentary from an array of industry contributors. Exchanges, mutual funds, investment companies and IB analysts provide coverage across stocks, options, futures, forex and fixed income. Visit: Interactive Brokers Group (https://www.interactivebrokers.com) Contact: firstname.lastname@example.org